BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2
BCL2 expression	Acute Myelogenous Leukemia	BCL2 expression	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 expression	Non-Hodgkin’s Lymphoma	BCL2 expression	Non-Hodgkin’s Lymphoma	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: C2 – Inclusion Criteria lenalidomide Sensitive : C2	lenalidomide Sensitive: C2 – Inclusion Criteria lenalidomide Sensitive : C2
BCL2 expression	Hodgkin Lymphoma	BCL2 expression	Hodgkin Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
BCL2 expression	Hodgkin Lymphoma	BCL2 expression	Hodgkin Lymphoma	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	S63845 Resistant: D – Preclinical S63845 Resistant : D	S63845 Resistant: D – Preclinical S63845 Resistant : D
BCL2 expression	Multiple Myeloma	BCL2 expression	Multiple Myeloma	S63845 Sensitive: D – Preclinical S63845 Sensitive : D	S63845 Sensitive: D – Preclinical S63845 Sensitive : D

BCL2 expression

Associations